Related Experiment Video
Updated: May 26, 2025
14:04
Applying a Three-dimensional Uniaxial Mechanical Stimulation Bioreactor System to Induce Tenogenic Differentiation of Tendon-Derived Stem Cells
Published on: August 1, 2020
5.9K
Targeting the IL-17A pathway for therapy in early-stage tendinopathy
Neal L Millar1, Iain B McInnes2, Frank Kolbinger3
1School of Infection and Immunity, University of Glasgow, Glasgow, UK neal.millar@glasgow.ac.uk.
RMD Open
|February 23, 2025
Summary
Interleukin 17A (IL-17A) drives tendinopathy by promoting inflammation and degeneration. Blocking the IL-17A pathway shows potential as a therapeutic strategy for early-stage tendinopathy.
Area of Science:
- Immunology
- Orthopedics
- Molecular Biology
Background:
- Tendinopathy presents a significant clinical and socioeconomic challenge with limited treatment options.
- Interleukin 17A (IL-17A) is implicated in tendinopathy pathogenesis.
- Understanding the IL-17A pathway's role is crucial for developing novel therapies.
Purpose of the Study:
- To elucidate the biological mechanisms of IL-17A pathway stimulation and blockade in tendinopathy.
- To investigate the differential expression of IL-17 family members in human rotator cuff tendinopathy.
- To evaluate the therapeutic potential of IL-17A blockade.
Main Methods:
- RT-qPCR analysis of IL-17 family member expression in human rotator cuff tendon biopsies.
- IL-17A stimulation of human tendon-derived cells to identify pathway signature genes.
- Ex vivo and in vivo studies in rat models to assess IL-17A pathway blockade effects.
Main Results:
- Differential expression of IL-17A observed in early-stage human tendinopathy.
- IL-17A stimulation upregulated key inflammatory and matrix-degrading genes.
- IL-17A blockade in rat models reduced inflammation, structural damage, and improved function.
Conclusions:
- IL-17A is a critical mediator of tendon inflammation and degeneration in tendinopathy.
- IL-17A blockade demonstrates therapeutic promise for early-stage tendinopathy.
- Targeting the IL-17A pathway offers a potential new treatment strategy.
Related Concept Videos
01:24T Cell Types and Functions
830
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
830
01:20The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K